Eli Lilly & Company (NYSE:LLY) | Lilly’s quarterly sales largely offset Cymbalta slide

January 30, 2014 at 11:09 AM EST

[Reuters] – Drugmaker Eli Lilly and Co’s quarterly revenue fell far less than expected, it reported on Thursday, as plunging sales of its Cymbalta depression treatment were largely offset by higher revenues for . . . → Read More: Eli Lilly & Company (NYSE:LLY) | Lilly’s quarterly sales largely offset Cymbalta slide Similar Articles: Stock Update: Colgate-Palmolive Company (NYSE:CL) – Colgate-Palmolive quarterly profit falls 6 pct Company Update: UnitedHealth Group Incorporated (NYSE:UNH) – UnitedHealth says quarterly profit rose, sees 2014 growth Merck & Co. Inc. (NYSE:MRK) – Germany’s Merck looks for deals to lift U.S. drug sales

Eli Lilly & Company (NYSE:LLY) [Reuters] – Drugmaker Eli Lilly and Co’s quarterly revenue fell far less than expected, it reported on Thursday, as plunging sales of its Cymbalta depression treatment were largely offset by higher revenues for most of its other prescription drugs. That compared with $827 million, or 74 cents per share, in the year-earlier quarter, when Lilly took charges for asset impairments and restructuring. “Company sales were stronger than thought, but a lot of that … [visit site to read more]